Emergency Management of NOAC Bleeding

Slides:



Advertisements
Similar presentations
Addressing the Challenges in Primary and Secondary Stroke Prevention
Advertisements

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Oral Anticoagulants and Reversal Agents
NOACs for Cancer-Associated Thrombosis:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
NOACs In Long-term VTE Treatment: A State Of The Art Review
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
The ABCs of AF.
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
How to Adjust Anticoagulant Dosing
New Oral Anticoagulants and VTE Management
VTE Treatment Conventional Approach
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Reversal Strategies for VKA: Truths and Misconceptions
Oral Anticoagulation in AF
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Atrial Fibrillation.
Advancing the Treatment of IBD With Biologics
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
DOACs and Urgent Bleeding
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
A Case Challenge.
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Managing Pulmonary Embolism Posthospital Discharge
Antithrombotics in Arterial Disease: Focus on Coronary Disease
Program Goals Background: Anticoagulation in Patients With VTE.
The ABCs of AF.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
NOACs and Reversal Agents
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
How to Adjust Anticoagulant Dosing
What's New in NOACs in AF?.
Presentation transcript:

Emergency Management of NOAC Bleeding

NOAC Trials: NOACs vs Warfarin Efficacy and Safety

NOACs VTE Extension Trials

NOAC Bleeding Pooled Analysis

Testing for NOAC Levels

Coagulation Assays for Measuring NOAC Anticoagulation Level

Nonspecific Reversal Agents of NOACs

Managing Emergency Bleeding Situations: Warfarin

Managing Emergency Bleeding Situations: NOACs

NOACs New Reversal Agents

Prothrombotic Complications of Reversal Agents

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)